{"id":"42142d2751c5","type":"article","url":"https://hartvaat.nl/2024/04/01/icosapent-ethyl-na-acs-reduce-it-subanalyse/","title":"Icosapent ethyl na ACS: REDUCE-IT subanalyse","title_en":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["acuut-coronair-syndroom"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehad889","source_url":"https://doi.org/10.1093/eurheartj/ehad889","authors":["Neila Sayah","Deepak L Bhatt","Michael Miller","Eliot A Brinton","Terry A Jacobson","Steven B Ketchum","Lixia Jiao","Armando Lira Pineda","Ralph T Doyle","Jean Claude Tardif","Christie M Ballantyne","Ph Gabriel Steg"],"significance":6,"published":"2024-04-01","source_date":"2024-04-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/levenslang-cardiovasculair-risico/"],"congress":"","summary_en":"This REDUCE-IT subanalysis in patients with recent ACS confirmed the cardiovascular benefit of icosapent ethyl in this high-risk post-acute setting.","created":"2026-07-03T10:30:51Z","updated":"2026-07-03T13:29:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Subanalyse van REDUCE-IT bij patiënten met recent ACS bevestigde het cardiovasculaire voordeel van icosapent ethyl in deze hoogrisicopopulatie. Het effect was vergelijkbaar met de totale populatie, wat vroege start na ACS ondersteunt.","abstract_original":""}